Proficio Capital Partners LLC Inhibrx, Inc. Transaction History

Proficio Capital Partners LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$26.75 - $46.02 $536,177 - $922,424	-20,044 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $1,107 - $1,663	44 Added 0.22%	20,044 $668,000
Q2 2021 Aug 16, 2021	BUY	$14.69 - $27.52 $293,800 - $550,400	20,000 New	20,000 $550,000
Q2 2021 Aug 16, 2021	SELL	$14.69 - $27.52 $293,800 - $550,400	-20,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$16.27 - $41.26 $325,400 - $825,200	20,000 New	20,000 $401,000

132

35.5M

64.8K

91.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Proficio Capital Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Proficio Capital Partners LLC with notifications on news.